Contact a Lawyer Now
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 23, 2019 to file lead plaintiff applications in a securities class action lawsuit against Karyopharm Therapeutics Inc. (NasdaqGS: KPTI), if they purchased the Company’s shares issued in connection with its April 2017 or May 2018 public offering or between March 2, 2017 and February 22, 2019, inclusive (the “Class Period”).
Karyopharm and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On February 22, 2019, the Federal Drug Administration (“FDA”) reported serious concerns with the Company’s drug, selinexor. Specifically, the FDA concluded that, contrary to the Company’s prior assurances, “[t]reatment with selinexor is associated with significant toxicity” with “limited efficacy.”
On this news, the price of Karyopharm’s shares plummeted.
If you purchased shares of Karyopharm and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (email@example.com), or fill out the form on this page.
The case is Allegheny County Employees’ Retirement System v. Karyopharm Therapeutics Inc., 1:19-cv-11597. Click here to read the case complaint.